Blar i forfatter "Omland, Torbjørn"

Viser treff 1-3 av 3

    • Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium 

      Brunner, Fabian J.; Waldeyer, Christoph; Ojeda, Francisco; Salomaa, Veikko; Kee, Frank; Sans, Susana; Thorand, Barbara; Giampaoli, Simona; Brambilla, Paolo; Tunstall-Pedoe, Hugh; Moitry, Marie; Iacoviello, Licia; Veronesi, Giovanni; Grassi, Guido; Mathiesen, Ellisiv B.; Söderberg, Stefan; Linneberg, Allan; Brenner, Hermann; Amouyel, Philippe; Ferrières, Jean; Tamosiunas, Abdonas; Nikitin, Yuriy P.; Drygas, Wojciech; Melander, Olle; Jöckel, Karl-Heinz; Leistner, David M.; Shaw, Jonathan E.; Panagiotakos, Demosthenes B.; Simons, Leon A.; Kavousi, Maryam; Vasan, Ramachandran S.; Dullaart, Robin P.F.; Wannamethee, S. Goya; Risérus, Ulf; Shea, Steven; de Lemos, James A.; Omland, Torbjørn; Kuulasmaa, Kari; Landmesser, Ulf; Blankenberg, Stefan (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-12-03)
      <i>Background</i> - The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term ...

    • Cardiac troponin I and T for ruling out coronary artery disease in suspected chronic coronary syndrome 

      Tveit, Sjur Hansen; Myhre, Peder Langeland; Hanssen, Tove Aminda; Forsdahl, Signe Helene; Iqbal, Amjid; Omland, Torbjørn; Schirmer, Henrik (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-01-18)
      To compare the performance of high-sensitivity cardiac troponin I and T (hs-cTnI; hs-cTnT) in diagnosing obstructive coronary artery disease (CAD<sub>50</sub>) in patients with suspected chronic coronary syndrome (CCS). A total of 706 patients with suspected CCS, referred for Coronary Computed Tomography Angiography, were included. cTn concentrations were measured using the Singulex hs-cTnI ...

    • Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial 

      Mecinaj, Albulena; Gulati, Geeta; Heck, Siri Lagethon; Holte, Espen; Fagerland, Morten Wang; Larsen, Alf Inge; Blix, Egil Støre; Geisler, Jürgen; Wethal, Torgeir; Omland, Torbjørn (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-09-27)
      Background - Recent advances in the treatment algorithms of early breast cancer have markedly improved overall survival. However, anthracycline- and trastuzumab-associated cardiotoxicity may lead to dose-reduction or halt in potentially life-saving adjuvant cancer therapy. Early initiated neurohormonal blockade may prevent or attenuate the cardiotoxicity-induced reduction in cardiac function, but ...